OBI Pharma Announces Poster Presentations at AACR 2019 for Novel Globo H Immuno-Oncology Therapeutics: OBI-888 and OBI-999

Poster Presentations to highlight on mechanism of action, anti-tumor efficacy and pharmacokinetics profile for OBI-888 (Globo H mAb) and OBI-999 (Globo H ADC) TAIPEI, Taiwan, March 28, 2019/OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H, SSEA-3 and SSEA-4), today announced that data highlighting OBI-888 (Globo […]

HOMEWhat’s NewNewsOBI Pharma Announces Poster Presentations at AACR 2019 for Novel Globo H Immuno-Oncology Therapeutics: OBI-888 and OBI-999

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2019.Feb.12

New Scientific Research provides link between Globo-series glycosphingolipids (GSLs) antigens and tumor survival in Breast Cancer

2019.Sep.03

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999